U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H30N4O2
Molecular Weight 358.4778
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PRACINOSTAT

SMILES

CCCCC1=NC2=CC(\C=C\C(=O)NO)=CC=C2N1CCN(CC)CC

InChI

InChIKey=JHDKZFFAIZKUCU-ZRDIBKRKSA-N
InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+

HIDE SMILES / InChI

Description

Pracinostat is a pan-histone deacetylase inhibitor being tested in phase II of clinical trials for the treatment of sarcoma, prostate cancer, acute myeloid leukemia, myelofibrosis, myelodysplastic syndrome. The drug was shown to be active in vitro on HCT116 and HL-60 cells.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Doses

AEs

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
The recommended dose is 60 mg given by mouth every other day, three times weekly for 3 weeks
Route of Administration: Oral
In Vitro Use Guide
Three micrograms of protein lysate from either HCT116 or HL-60 cells were treated for 24 hours with 2 uM pracinostat to obtain a strong acetylation of K9 and K14 of histone H3. The lowest concentration of the drug leading to acH3 was 22 ng/mL (0.06 uM) for both HCT-116 and HL-60 cells treated for 24 hours with pracinostat. In HL-60 cells, maximal acH3 levels were reached at 1 uM not increasing further after treatment with 2 uM.